Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 26:80:11573.
doi: 10.3389/bjbs.2023.11573. eCollection 2023.

The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders

Affiliations

The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders

Hanaan Kareem Al-Zubaidi et al. Br J Biomed Sci. .

Abstract

Background: B-Cell Lymphoproliferative Disorders (B-LPDs) are a group of heterogenous disorders characterised by the accumulation of B-cells in peripheral blood, bone marrow, lymph nodes and spleen. They have a variable disease course and outcome and many share similar features making differential diagnosis challenging. Therefore, accurate diagnosis is fundamental in particular for determining treatment options. Immunophenotyping by flow cytometry plays a crucial role in the diagnosis of B-LPDs. However, overlapping immunophenotyping patterns exist and the use of novel monoclonal antibodies has become increasingly important in immunophenotyping analysis. More recently differential expression of CD200 has been reported in various B-LPDs and that CD200 may improve the differentiation between chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). In this study CD200 expression is evaluated in different B-LPDs. Methods: A total of 100 samples were collected and analysed by immunophenotyping flow cytometry over a period of 1 year (2017-2018), by a panel of monoclonal antibodies including CD200. The percentage of CD200 and its expression intensity was evaluated and compared between different groups of B-LPDs. Results: All of the 50 cases of CLL expressed CD200 with moderate to bright intensity, 6 MCL cases lacked the expression of CD200. Furthermore, all 5 cases of hairy cell leukaemia (HCL) expressed CD200. Out of all B-LPDs evaluated, CD200 expression in HCL cases was noted to be the brightest. The other 39 cases were not found to be B-LPDs. Conclusion: CD200 has an important role in differentiating CLL from MCL, HCL has a consistent bright expression of CD200. By adding CD200 to the combinations of markers in routine testing panel, Immunophenotyping by flow cytometry can be an effective tool in the diagnosis of B-LPDs especially in cases with atypical immunophenotyping pattern. Our result support that CD200 can be added to routine testing panel as it is useful in differentiating them.

Keywords: chronic lymphocytic leukaemia; flow cytometry; hairy cell leukaemia; immunophenotyping; mantle cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow cytometry antigen expression interpretation.
FIGURE 2
FIGURE 2
Flow cytometry scatter plot showing expression pattern in CLL [Row (A)] CLL with a negative FMC7, [Row (B)] positive CD23 and CD5 expression. And, [Row (C)] a bright CD200 and dim kappa ex-pression.
FIGURE 3
FIGURE 3
Box plot showing the % of cells with positive expression for CD200 in B-LPDs. The lines inside the box and bars represent median and interquartile ranges. Asterisks and circles represent CD200 values not included between the vertical lines (outliners).

References

    1. Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ. Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma. Am J Clin Pathol (2007) 127(2):176–81. 10.1309/5EL22BH45PHUPM8P - DOI - PubMed
    1. WHO. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; (2017).
    1. WHO. Chronic Lymphocytic Leukemia Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. (2015).
    1. UK CR. Chronic Lymphocytic Leukaemia (CLL) Incidence Statistics (2015). Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... .
    1. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, et al. Improvement of the Chronic Lymphocytic Leukemia Scoring System With the Monoclonal Antibody SN8 (CD79b). Am J Clin Pathol (1997) 108(4):378–82. 10.1093/ajcp/108.4.378 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources